DVAX

ANALYST NOTE: DVAX (Dynavax Technologies Corporation) Date: 2026-06-13 Current Price: $15.50

1. Structural Readiness

State: Context-only Conservative Entry: — Breakout Level: — Extension: — ATR at Breakout: — ATR Current: 0.7% (Sub-threshold)

Structural Assessment:

2. Thesis Layer

Thesis Classification: TACTICAL / SETUP-LED Secular Exposure: None Named

At this date, Dynavax Technologies is not anchored to a named macro or secular thesis within the StoryStocks framework. The investment case is strictly tactical, driven by the quality of the technical setup (which is currently absent) and the underlying business fundamentals. There is no broad thematic overlay (e.g., "Global Vaccination Surge" or "Biotech Re-rating") assigned to this name as of 2026-06-13. The conviction must be derived solely from the execution of the business plan and the eventual formation of a technical structure, rather than a pre-existing macro narrative.

3. Business Fundamentals

Company Profile: Dynavax Technologies Corporation is a biopharmaceutical firm specializing in the development and market introduction of innovative vaccines, primarily operating in the United States. The company's core business model relies on the commercialization of its lead product, HEPLISAV-B, a two-dose hepatitis B vaccine approved for adults 18 years and older in the U.S. and Europe. The company also produces and distributes CpG 1018, the specific adjuvant ingredient used in HEPLISAV-B, creating a dual-revenue stream of product sales and adjuvant licensing/distribution.

Operational Status & Management Expectations (as of 2025-11-05): Management has provided specific guidance on revenue and market share targets, which remain the primary drivers of the business case as of June 2026:

• Revenue Guidance: In the November 2025 earnings transcript, management reiterated expectations for HEPLISAV-B net product revenue to be in the range of $315 million to $325 million for the year.
• Profitability: Management expects to achieve adjusted EBITDA of at least $80 million for the year.
• Market Share Progress: As of the reporting period, HEPLISAV-B generated approximately $90 million in net product revenue. The estimated U.S. adult hepatitis B vaccine market share reached 46%, up from 44% in the prior year. Within the retail segment, market share grew to 63% (compared to 55% in Q3 of the prior year).
• Long-Term Targets: Management stated they remain on track to achieve a long-term goal of at least 60% total market share in the U.S. by 2030. They expect the overall market to peak at more than $900 million in the U.S. by 2030.
• Pipeline Status: Management indicated they look forward to sharing top-line immunogenicity and safety results from Part 2 and 12-month follow-up data from Part 1 in the second half of 2026. Additionally, Vaxart (a partner/related entity in the transcript context) expects top-line data by the end of 2026.

4. Archetype and Conviction

Archetype: Quality Compounder Rationale: The name fits the Quality Compounder archetype based on the evidence of a profitable, growing franchise with a clear path to market dominance.

• Margin Inflector: The company has moved from a development-stage biotech to a profitable entity, with management guiding for adjusted EBITDA of at least $80 million on ~$320M revenue.
• Growth Leader: The business is executing on a clear strategy to capture market share in a growing market (driven by ACIP universal recommendations and a catch-up cohort of >100 million unprotected adults).
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.4906 for FY1 and $0.6689 for FY2. At a current price of $15.50, the stock trades at approximately 31x FY1 EPS and 23x FY2 EPS. This valuation reflects the market's pricing of the compounder status and the execution of the 60% market share target.

Conviction Stack:

• Thesis Strength: Moderate. The business fundamentals are strong, but the lack of a named secular thesis limits the "narrative" upside.
• Evidence Quality: High. The evidence base is robust, citing specific revenue figures, market share percentages, and clear management guidance from late 2025.
• Structural Quality: Low. The technical setup is currently non-existent (context-only). The ATR of 0.7% is sub-threshold, indicating a lack of volatility necessary to define a high-conviction entry or stop.
• Setup Readiness: None. No coil is forming or confirmed.
• Rerating Potential: Dependent on the release of the "Part 2" and "Part 1" data in the second half of 2026, which could validate the long-term growth story.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Data Readiness: Successful release of the top-line immunogenicity and safety results from Part 2 and Part 1 follow-up data in the second half of 2026, confirming the pipeline's potential to extend the growth runway beyond HEPLISAV-B.
• Market Share Acceleration: Evidence that the 46% market share is accelerating toward the 60% target faster than the 2030 timeline, potentially driven by new retail channel penetration.

What Would Invalidate the Case:

• Data Failure: If the data expected in the second half of 2026 shows inferior immunogenicity or safety concerns compared to competitors, the "Quality Compounder" thesis would be structurally broken.
• Revenue Miss: A significant deviation below the $315M–$325M revenue guidance or a failure to maintain the 46% market share would signal execution risk.

Gaps in Evidence Base:

• Pipeline Specifics: While data is expected in H2 2026, the specific details of the "Part 2" and "Part 1" studies (e.g., specific indications, comparator data) are not yet available in the evidence base as of June 2026.
• Competitive Landscape: The evidence does not detail specific competitive threats or pricing pressure from other hepatitis B vaccines in the U.S. market.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Management guidance for $315M-$325M revenue and $80M EBITDA; 46% market share achieved with clear path to 60% by 2030; forward EPS of $0.49 and $0.67. Key risks: Technical setup is currently non-existent (context-only) with sub-threshold volatility; pending data release in H2 2026 carries binary risk; lack of named secular thesis limits narrative support. Sizing hint: Position size should be zero until a technical structure forms; current price action does not support a risk-defined entry. Expected path: Management expects to deliver top-line data in H2 2026; if data is positive, the business case for a compounder strengthens, potentially triggering a technical breakout. Expected horizon: 6 to 12 months, aligned with the H2 2026 data release window.